Page 24 - TD-3-3

Tumor Discovery Immune and epigenetic therapies for TNBC

doi: 10.3389/fimmu.2019.03136 115. Keenan TE, Tolaney SM. Role of immunotherapy in
triple-negative breast cancer. J Natl Compr Canc Netw.
105. Wang X, Brea LT, Yu J. Immune modulatory functions of
EZH2 in the tumor microenvironment: Implications in 2020;18:479-489.
cancer immunotherapy. Am J Clin Exp Urol. 2019;7:85-91. doi: 10.6004/jnccn.2020.7554
106. Wong KK. DNMT1: A key drug target in triple-negative 116. Jacquemier J, Bertucci F, Finetti P, et al. High expression of
breast cancer. Semin Cancer Biol. 2021;72:198-213. indoleamine 2,3-dioxygenase in the tumour is associated
with medullary features and favourable outcome in basal-
doi: 10.1016/j.semcancer.2020.05.010
like breast carcinoma. Int J Cancer. 2012;130(1):96-104.
107. Ropero S, Esteller M. The role of histone deacetylases
(HDACs) in human cancer. Mol Oncol. 2007;1:19-25. doi: 10.1002/ijc.25979
117. Noonepalle SK, Gu F, Lee EJ, et al. Promoter methylation
doi: 10.1016/j.molonc.2007.02.001
modulates indoleamine 2,3-dioxygenase 1 induction by
108. Morand S, Stanbery L, Walter A, Rocconi RP, Nemunaitis J. activated T cells in human breast cancers. Cancer Immunol
BRCA1/2 mutation status impact on autophagy and immune Res. 2017;5(4):330-344.
response: Unheralded target. JNCI Cancer Spectrum.
2021;4(6):pkaa077. doi: 10.1158/2326-6066.CIR-16-0182
118. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation
doi: 10.1093/jncics/pkaa077
of PD-L1, IDO, and T(regs) in the melanoma tumor
109. Kim S, Park S, Cho MS, Lim W, Moon BI, Sung SH. Strong microenvironment is driven by CD8(+) T cells. Sci Transl
correlation of indoleamine 2,3-dioxygenase 1 expression Med. 2013;5:200ra116.
with basal-like phenotype and increased lymphocytic
infiltration in triple-negative breast cancer. J Cancer. doi: 10.1126/scitranslmed.3006504
2017;8(1):124-130. 119. Song X, Si Q, Qi R, et al. Indoleamine 2,3-dioxygenase 1:
A promising therapeutic target in malignant tumor. Front
doi: 10.7150/jca.17437
Immunol. 2021;12:800630.
110. Dill EA, Dillon PM, Bullock TN, Mills AM. IDO expression
in breast cancer: An assessment of 281 primary and doi: 10.3389/fimmu.2021.800630.
metastatic cases with comparison to PD-L1. Mod Pathol. 120. Zhai L, Spranger S, Binder DC, et al. Molecular pathways:
2018;31(10):1513-1522. Targeting IDO1 and other tryptophan dioxygenases for
cancer immunotherapy. Clin Cancer Res. 2015;21:5427-5433.
doi: 10.1038/s41379-018-0061-3
doi: 10.1158/1078-0432.CCR-15-0420
111. Asghar K, Loya A, Rana IA, et al. Association between
cyclooxygenase-2 and indoleamine 2,3-dioxygenase 121. Sun L. Advances in the discovery and development of
expression in breast cancer patients from Pakistan. Asian selective heme-displacing IDO1 inhibitors. Expert Opin
Pac J Cancer Prev. 2019;20(11):3521-3525. Drug Discov. 2020;15:1223-1232.
doi: 10.31557/APJCP.2019.20.11.3521 doi: 10.1080/17460441.2020.1781811
112. Costa RLB, Czerniecki BJ. Clinical development of 122. Pallotta MT, Rossini S, Suvieri C, et al. Indoleamine
immunotherapies for HER2+ breast cancer: A review of 2,3-dioxygenase 1 (IDO1): An up-to-date overview
HER2-directed monoclonal antibodies and beyond. NPJ of an eclectic immunoregulatory enzyme. FEBS J.
Breast Cancer. 2020;6:10. 2022;289(20):6099-6118.
doi: 10.1038/s41523-020-0153-3 doi: 10.1111/febs.16086
113. Jing R, Bai S, Zhang P, et al. IDO-1 impairs antitumor 123. Tomek P, Palmer BD, Flanagan JU, Sun C, Raven EL,
immunity of natural killer cells in triple-negative breast Ching LM. Discovery and evaluation of inhibitors to the
cancer via up-regulation of HLA-G. Breast Cancer. immunosuppressive enzyme indoleamine 2,3-dioxygenase
2024;31(1):135-147. 1 (IDO1): Probing the active site-inhibitor interactions. Eur
J Med Chem. 2017;126:983-996.
doi: 10.1007/s12282-023-01522-w
doi: 10.1016/j.ejmech.2016.12.029
114. Carter JM, Polley MYC, Leon-Ferre RA, et al. Characteristics
and spatially defined immune (micro) landscapes of early- 124. Munn DH, Mellor AL. IDO in the tumor microenvironment:
stage PD-L1-positive triple-negative breast cancer. Clin Inflammation, counter-regulation, and tolerance. Trends
Cancer Res. 2021;27(20):5628-5637. Immunol. 2016;37:193-207.
doi: 10.1158/1078-0432.CCR-21-0343 doi: 10.1016/j.it.2016.01.002

Volume 3 Issue 3 (2024) 18 doi: 10.36922/td.3383